Suppr超能文献

自身免疫性疾病与意义未明的单克隆丙种球蛋白病进展风险较低相关。

Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance.

作者信息

Baldursdóttir Theodóra Rún, Löve Þorvarður Jón, Gíslason Gauti Kjartan, Björkholm Magnus, Mellqvist Ulf-Henrik, Lund Sigrun Helga, Blimark Cecilie Hveding, Turesson Ingemar, Hultcrantz Malin, Landgren Ola, Kristinsson Sigurður Yngvi

机构信息

Landspítali, National University Hospital, Reykjavík, Iceland.

Faculty of Medicine, University of Iceland, Reykjavik, Iceland.

出版信息

Eur J Haematol. 2021 Mar;106(3):380-388. doi: 10.1111/ejh.13563. Epub 2020 Dec 28.

Abstract

OBJECTIVES AND METHODS

We conducted a population-based study including 19 303 individuals diagnosed with MGUS in Sweden from 1985 to 2013, with the aim to determine whether a prior history of autoimmune disease, a well-described risk factor for MGUS is a risk factor for progression of MGUS to multiple myeloma (MM) or lymphoproliferative diseases (LPs). Using the nationwide Swedish Patient registry, we identified MGUS cases with versus without an autoimmune disease present at the time of MGUS diagnosis and estimated their risk of progression.

RESULTS

A total of 5612 (29.1%) MGUS cases had preceding autoimmune diseases. Using Cox proportional hazards models, we found the risk of progression from MGUS to MM (HR = 0.83, 95% CI 0.73-0.94) and LPs (HR = 0.84, 95% CI 0.75-0.94) to be significantly lower in MGUS cases with prior autoimmune disease (compared to MGUS cases without).

CONCLUSIONS

In this large population-based study, a history of autoimmune disease was associated with a reduced risk of progression from MGUS to MM/other LPs. Potential underlying reason is that MGUS caused by chronic antigen stimulation is biologically less likely to undergo the genetic events that trigger progression. Our results may have implications in clinical counseling for patients with MGUS and underlying autoimmune disease.

摘要

目的与方法

我们开展了一项基于人群的研究,纳入了1985年至2013年在瑞典诊断为意义未明的单克隆丙种球蛋白病(MGUS)的19303名个体,旨在确定自身免疫性疾病(一种已明确的MGUS风险因素)既往史是否为MGUS进展为多发性骨髓瘤(MM)或淋巴增殖性疾病(LP)的风险因素。利用瑞典全国患者登记系统,我们确定了MGUS诊断时伴有或不伴有自身免疫性疾病的MGUS病例,并估计了它们的进展风险。

结果

共有5612例(29.1%)MGUS病例有自身免疫性疾病既往史。使用Cox比例风险模型,我们发现既往有自身免疫性疾病的MGUS病例进展为MM(风险比[HR]=0.83,95%置信区间[CI]0.73 - 0.94)和LP(HR = 0.84,95% CI 0.75 - 0.94)的风险显著低于(与无自身免疫性疾病的MGUS病例相比)。

结论

在这项大型基于人群的研究中,自身免疫性疾病史与MGUS进展为MM/其他LP的风险降低相关。潜在的根本原因是由慢性抗原刺激引起的MGUS在生物学上不太可能发生触发进展的基因事件。我们的结果可能对MGUS及潜在自身免疫性疾病患者的临床咨询有影响。

相似文献

1
Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance.
Eur J Haematol. 2021 Mar;106(3):380-388. doi: 10.1111/ejh.13563. Epub 2020 Dec 28.
5
Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a systematic review.
Cancer Epidemiol Biomarkers Prev. 2014 Feb;23(2):332-42. doi: 10.1158/1055-9965.EPI-13-0695. Epub 2014 Jan 22.
6
Untangling fracture risk in monoclonal gammopathy of undetermined significance: A population-based cohort study.
Eur J Haematol. 2021 Jul;107(1):137-144. doi: 10.1111/ejh.13633. Epub 2021 Apr 28.
9
Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis.
Clin Lymphoma Myeloma Leuk. 2015 Mar;15(3):177-186.e4. doi: 10.1016/j.clml.2014.09.004. Epub 2014 Sep 28.
10
A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance.
Eur J Haematol. 2017 Jul;99(1):80-90. doi: 10.1111/ejh.12894. Epub 2017 May 11.

引用本文的文献

1
Association of ANA and SSA autoantibodies with progression-free survival in multiple myeloma: a retrospective cohort study.
Front Oncol. 2025 Feb 21;15:1529678. doi: 10.3389/fonc.2025.1529678. eCollection 2025.
2
Autoimmune Diseases and Plasma Cells Dyscrasias: Pathogenetic, Molecular and Prognostic Correlations.
Diagnostics (Basel). 2024 May 29;14(11):1135. doi: 10.3390/diagnostics14111135.
7
Editorial: The Role of Microorganisms in Multiple Myeloma.
Front Immunol. 2022 Jun 30;13:960829. doi: 10.3389/fimmu.2022.960829. eCollection 2022.
8
Autoimmunity, Infections, and the Risk of Monoclonal Gammopathy of Undetermined Significance.
Front Immunol. 2022 Apr 28;13:876271. doi: 10.3389/fimmu.2022.876271. eCollection 2022.

本文引用的文献

1
Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance.
N Engl J Med. 2018 Jan 18;378(3):241-249. doi: 10.1056/NEJMoa1709974.
3
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
Lancet Oncol. 2014 Nov;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5. Epub 2014 Oct 26.
4
Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a systematic review.
Cancer Epidemiol Biomarkers Prev. 2014 Feb;23(2):332-42. doi: 10.1158/1055-9965.EPI-13-0695. Epub 2014 Jan 22.
6
Incidental finding of monoclonal gammopathy in blood donors: a follow-up study.
Blood Transfus. 2012 Jul;10(3):338-43. doi: 10.2450/2012.0083-11. Epub 2012 Mar 28.
7
Prevalence of monoclonal gammopathy of undetermined significance in Thailand.
Int J Hematol. 2012 Feb;95(2):176-81. doi: 10.1007/s12185-011-0995-4. Epub 2012 Jan 12.
8
Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study.
Blood. 2011 Dec 8;118(24):6284-91. doi: 10.1182/blood-2011-04-347559. Epub 2011 Oct 13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验